SCHEMBL5166992

SCHEMBL5166992

CCOC(=O)c1nn[nH]c1C(=O)Nc1ccc(OC)c(OC)c1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.56
MAPT P10636 4/20 0.56
MEN1 O00255 3/20 0.56
GAA P10253 1/20 0.56
SMN1; SMN2 Q16637 6/20 0.51
ALDH1A1 P00352 3/20 0.48
MAPK1 P28482 2/20 0.48
RAB9A P51151 3/20 0.47
NTRK1 P04629 1/20 0.47
NTRK2 Q16620 1/20 0.47
HTT P42858 1/20 0.47
LMNA P02545 1/20 0.46
NPC1 O15118 2/20 0.46
KDM4E B2RXH2 2/20 0.46
TP53 P04637 2/20 0.46
CYP1A2 P05177 2/20 0.45
CYP2C19 P33261 2/20 0.45
CYP2C9 P11712 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5167917 0.80 CYP2C19 (0.50) KMT2AMAPTMEN1GAASMN1; SMN2
SCHEMBL5165358 0.77 CYP2C19 (0.49) KMT2AMAPTMEN1GAASMN1; SMN2
SCHEMBL5517831 0.75 MAPT (0.51) KMT2AMAPTMEN1GAAALDH1A1
SCHEMBL10817064 0.73 SMN1; SMN2 (0.71) KMT2AMAPTMEN1GAASMN1; SMN2
SCHEMBL5648877 0.72 KDM4E (0.46) KMT2AMAPTMEN1SMN1; SMN2ALDH1A1
SCHEMBL5515197 0.71 TSHR (0.54) KMT2AMAPTMEN1GAAALDH1A1
SCHEMBL15682719 0.71 MAPT (0.63) KMT2AMAPTMEN1GAASMN1; SMN2
SCHEMBL5508703 0.70 POLB (0.46) KMT2AMAPTMEN1SMN1; SMN2ALDH1A1
SCHEMBL5648880 0.70 KDM4E (0.47) KMT2AMAPTMEN1GAAALDH1A1
SCHEMBL21296870 0.69 KDM4E (0.51) KMT2AMAPTMEN1SMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7238719-B2 Process for producing 1,2,3-Triazole compounds MEIJI SEIKA KAISHA, LTD. (JP) 2007-07-03 US disclosed
EP-1471058-B1 PROCESS FOR PRODUCING 1,2,3-TRIAZOLE COMPOUND MEIJI SEIKA KAISHA (JP) 2007-04-11 EP disclosed
US-20050080270-A1 Process for producing 1 2 3 triazole compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2005-04-14 US disclosed
EP-1471058-A1 PROCESS FOR PRODUCING 1,2,3-TRIAZOLE COMPOUND MEIJI SEIKA KAISHA LTD. (JP) 2004-10-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050080270-A1 Process for producing 1 2 3 triazole compound RPS27L, KARS1, STK38L KMT2A 1464/4885MAPT 4274/4885MEN1 1611/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.